Evidence map›Paper›PMID 42432013›Full record

ArticleMolecular psychiatry2026

Experimental change in temperament: Conversion of the low exploratory phenotype into highly explorative by overexpression of GDNF in the rat striatum.

Jaanus Harro, Aet O'Leary, Marianna Norden, Kristi Liiver, Margus Kanarik, J Arturo García-Horsman, Sven Sakson, Pilleriin Kupper, Karita Laugus, Sirin Korulu and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Jaanus HarroDivision of Neuropsychopharmacology, Institute of Chemistry, University of Tartu, Ravila 14A Chemicum, 50411, Tartu, Estonia. jaanus.harro@ut.ee.ORCID http://orcid.org/0000-0002-4484-2096
Aet O'LearyDivision of Neuropsychopharmacology, Institute of Chemistry, University of Tartu, Ravila 14A Chemicum, 50411, Tartu, Estonia.ORCID http://orcid.org/0000-0001-6783-4729
Marianna NordenSchool of Natural Sciences and Health, Tallinn University, Narva 25, 10120, Tallinn, Estonia.
Kristi LiiverSchool of Natural Sciences and Health, Tallinn University, Narva 25, 10120, Tallinn, Estonia.
Margus KanarikDivision of Neuropsychopharmacology, Institute of Chemistry, University of Tartu, Ravila 14A Chemicum, 50411, Tartu, Estonia.ORCID http://orcid.org/0000-0002-3326-5297
J Arturo García-HorsmanDrug Research Program, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00014, Helsinki, Finland.
Sven SaksonInstitute of Biotechnology, HiLIFE, University of Helsinki, Viikinkaari 5D, 00790, Helsinki, Finland.
Pilleriin KupperDivision of Neuropsychopharmacology, Institute of Chemistry, University of Tartu, Ravila 14A Chemicum, 50411, Tartu, Estonia.
Karita LaugusDivision of Neuropsychopharmacology, Institute of Chemistry, University of Tartu, Ravila 14A Chemicum, 50411, Tartu, Estonia.ORCID http://orcid.org/0009-0001-8228-8233
Sirin KoruluDivision of Neuropsychopharmacology, Institute of Chemistry, University of Tartu, Ravila 14A Chemicum, 50411, Tartu, Estonia.ORCID http://orcid.org/0000-0001-6762-0659
Indrek TeinoInstitute of Biotechnology, HiLIFE, University of Helsinki, Viikinkaari 5D, 00790, Helsinki, Finland.ORCID http://orcid.org/0000-0002-2381-4715
Tõnis OrgInstitute of Molecular and Cell Biology, University of Tartu, Riia 23, 50107, Tartu, Estonia.ORCID http://orcid.org/0000-0003-3071-2183
Ilmari ParkkinenDrug Research Program, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00014, Helsinki, Finland.
Tanel KaartInstitute of Veterinary Medicine and Animal Sciences, Estonian University of Life Sciences, Fr. R. Kreutzwaldi 1, 51006, Tartu, Estonia.ORCID http://orcid.org/0000-0002-8936-768X
Päivi LindholmInstitute of Biotechnology, HiLIFE, University of Helsinki, Viikinkaari 5D, 00790, Helsinki, Finland.ORCID http://orcid.org/0000-0003-3022-5035
Sophie ImbeaultSchool of Natural Sciences and Health, Tallinn University, Narva 25, 10120, Tallinn, Estonia.ORCID http://orcid.org/0000-0003-1454-9267
Helen PoskaSchool of Natural Sciences and Health, Tallinn University, Narva 25, 10120, Tallinn, Estonia.ORCID http://orcid.org/0000-0002-1346-4862
Brandon K HarveyNational Institute on Drug Abuse, National Institutes of Health, 251 Bayview Boulevard, Baltimore, MD, 21224, USA.
Mikko AiravaaraDrug Research Program, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00014, Helsinki, Finland.
Ruth ShimmoSchool of Natural Sciences and Health, Tallinn University, Narva 25, 10120, Tallinn, Estonia.
Mart SaarmaInstitute of Biotechnology, HiLIFE, University of Helsinki, Viikinkaari 5D, 00790, Helsinki, Finland.ORCID http://orcid.org/0000-0001-5543-7160

Funding

Cure Parkinson's Trust (CPT) MS02EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) 810645Eesti Teadusagentuur (Estonian Research Council) PRG1213Sigrid Juséliuksen Säätiö (Sigrid Jusélius Foundation) Visiting Professorship
6 · The paper itself

Abstract

Major vulnerability factors for psychiatric disorders such as depression, that often prevent complete remission and lead to relapses, are temperamental. In a rat model of clustered persistent high-anxiety/low-motivation, we have found that overexpression of glial cell line-derived neurotrophic factor (GDNF) by intra-striatally administered adeno-associated virus vector completely converts the passive coping style of low exploratory rats into an active one, similar to high exploratory rats. This conversion of the behavioural strategy developed gradually over repeated testing, and was associated with increased catecholamine metabolism in several brain regions and changes in the regulation of serotonin neurotransmission. An increase in dopamine transporter availability in the striatum was necessary for the phenotype conversion. Associated changes in striatal gene expression included key regulators of monoamine storage and epitranscriptomic regulation. The increase in GDNF signalling also caused alterations in levels and regional covariation of oxidative metabolism, suggestive of a reorganization of neural activity throughout the brain. Thus, neurotrophic factors, GDNF in particular, may play a pivotal role in the development, persistence and alteration of temperament/personality traits, and therefore constitute a potential target for treatment of chronic, relapsing psychiatric disorders.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.